Aptose posts Q1 net loss of $9.6M; advances TUS+VEN+HMA triplet to clinical site activation

Aptose Biosciences Inc.

2024-Q1 EPS reported -$0.73 vs consensus -$22.64 ▲ beat (+96.8%)

Net loss of $9.6M ($0.73/share) vs $13.7M ($2.22) a year ago; cash $9.3M expected to fund through August 2024.
Tuspetinib triplet (TUS+VEN+HMA) protocol for ND AML submitted to FDA; clinical sites being activated; initial data expected Q4 2024.
Stockholders' equity positive $137k as of March 31, but Nasdaq equity deficiency notice remains; compliance plan due May 17, 2024.
EHA 2024 poster accepted for TUS monotherapy and TUS+VEN doublet data in R/R AML; preclinical data showing TUS activity against VEN-resistant AML.
Nasdaq compliance regained regarding Hanmi warrant issue; second deficiency notice for equity minimum still open.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Aptose Biosciences Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.